asthma
highli
preval
chronic
respiratori
diseas
affect
million
peopl
worldwid
signific
fraction
cost
morbid
asthma
deriv
acut
care
asthma
exacerb
unit
state
alon
approxim
million
outpati
visit
million
emerg
room
visit
hospit
year
manag
acut
asthma
common
respiratori
virus
especi
rhinovirus
caus
major
exacerb
children
adult
infect
airway
epitheli
cell
rhinoviru
caus
releas
proinflammatori
cytokin
chemokin
well
recruit
inflammatori
cell
particularli
neutrophil
lymphocyt
eosinophil
host
respons
viral
infect
like
influenc
suscept
asthma
exacerb
least
one
exacerb
import
risk
factor
recurr
exacerb
suggest
exacerbationpron
subset
asthmat
factor
underli
exacerbationpron
phenotyp
incomplet
understood
includ
extrins
factor
cigarett
smoke
medic
noncompli
psychosoci
factor
comorbid
gastroesophag
reflux
diseas
rhinosinus
obes
intoler
nonsteroid
antiinflammatori
medic
well
intrins
factor
defici
epitheli
cell
product
antivir
type
interferon
ifna
ifnb
better
understand
biolog
mechan
host
suscept
recurr
exacerb
import
develop
effect
prevent
treatment
aim
reduc
signific
cost
morbid
associ
import
global
health
problem
asthma
highli
preval
chronic
respiratori
condit
character
revers
airflow
obstruct
airway
hyperrespons
ahr
airway
inflamm
produc
symptom
short
breath
cough
wheez
chest
tight
clear
consensu
definit
asthma
exacerb
clinic
trial
usual
defin
sever
exacerb
need
treatment
system
corticosteroid
hospit
admiss
emerg
treatment
worsen
asthma
decreas
morn
peak
baselin
consecut
day
public
health
burden
chronic
asthma
increas
past
two
decad
acut
exacerb
asthma
particularli
import
costli
problem
million
peopl
affect
asthma
worldwid
accord
center
diseas
control
prevent
nation
center
health
statist
estim
us
preval
asthma
unit
state
million
popul
highest
preval
rate
report
unit
kingdom
new
zealand
asthma
exacerb
result
million
outpati
visit
million
emerg
room
visit
hospit
death
unit
state
alon
casefat
asthma
unit
state
estim
per
wide
variat
across
europ
eg
per
finland
per
denmark
asthmat
exacerb
requir
treatment
emerg
depart
hospit
patient
account
total
direct
cost
larg
part
averag
cost
hospit
admiss
asthma
treatment
unit
state
us
purpos
review
examin
epidemiolog
featur
acut
asthma
exacerb
summar
recent
advanc
understand
clinic
biolog
featur
asthma
exacerb
also
review
potenti
mechan
underli
suscept
subgroup
asthmat
recurr
sever
exacerb
accord
latest
nih
nation
asthma
educ
prevent
guidelin
asthma
exacerb
acut
subacut
episod
progress
worsen
short
breath
cough
wheez
chest
tight
combin
symptom
character
decreas
expiratori
airflow
object
measur
lung
function
spirometri
peak
flow
episod
distress
patient
result
consider
util
health
care
resourc
loss
work
product
school
attend
exacerb
manag
outpati
set
unit
state
million
visit
physician
offic
hospit
outpati
depart
acut
asthma
still
left
million
patient
requir
emerg
room
manag
asthma
exacerb
sever
exacerb
result
hospit
constitut
onethird
total
billion
us
annual
asthmarel
health
care
expenditur
agenc
healthcar
research
qualiti
sponsor
nationwid
inpati
sampl
ni
largest
allpay
sourc
data
hospit
patient
unit
state
data
show
admiss
asthma
year
among
intub
respiratori
failur
associ
acut
sever
asthma
tabl
data
ni
demonstr
age
group
experienc
hospit
similar
rate
slight
predomin
age
rang
repres
admiss
asthma
howev
ni
show
mortal
increas
dramat
increas
age
children
adolesc
lowest
mortal
rate
elderli
highest
mortal
asthma
notabl
among
approxim
asthmat
patient
die
acut
asthma
annual
unit
state
major
approxim
still
occur
outsid
hospit
asthma
exacerb
common
femal
male
femal
twice
like
male
hospit
asthma
howev
asthma
preval
higher
postpubert
femal
postpubert
male
fact
larg
part
explan
higher
number
adult
femal
seek
care
acut
asthma
higher
preval
asthma
adult
femal
contrast
higher
preval
asthma
male
children
differ
gender
predisposit
asthma
adulthood
vs
childhood
like
reflect
complic
effect
sex
hormon
asthma
pathogenesi
evid
role
estrogen
asthma
come
observ
increas
asthma
exacerb
mens
higher
incid
adultonset
asthma
women
take
hormon
replac
therapi
anim
model
race
ethnic
also
play
import
role
risk
asthma
exacerb
african
american
hispan
patient
asthma
higher
risk
caucasian
admit
hospit
manag
exacerb
associ
explain
differ
socioeconom
statu
asthma
sever
differ
asthma
therapi
although
overal
mortal
rate
asthma
consider
higher
among
african
american
caucasian
explain
factor
relat
outofhospit
mortal
inhospit
mortal
compar
group
hospit
factor
may
includ
differ
access
health
care
poor
prevent
manag
delay
seek
medic
attent
unit
state
preval
selfreport
asthma
exacerb
particularli
high
among
american
puertorican
ancestri
contrast
rel
low
frequenc
asthma
exacerb
hispan
subgroup
mexican
american
reason
increas
exacerb
risk
unclear
could
includ
social
environment
genet
factor
signific
progress
made
identifi
potenti
genet
factor
associ
develop
asthma
puertorican
genet
suscept
factor
exacerb
risk
explor
rate
hospit
asthma
compar
across
season
respiratori
virus
caus
exacerb
sever
differ
virus
caus
exacerb
includ
rhinoviru
influenza
coronaviru
differ
season
variat
exampl
exacerb
precipit
rhinoviru
document
throughout
year
predilect
late
spring
aprilmay
fall
month
septembernovemb
interestingli
hospit
mortal
asthma
highest
winter
month
januarymarch
perhap
relat
higher
rate
influenza
infect
longitudin
adult
prospect
studi
demonstr
relationship
obes
asthma
although
relationship
may
confound
part
age
gender
comorbid
gastroesophag
reflux
diseas
gerd
sleepdisord
breath
data
longitudin
studi
suggest
may
also
link
obes
risk
asthma
exacerb
includ
exacerb
sever
enough
warrant
treatment
emerg
depart
hospit
mechan
obes
could
risk
factor
asthma
exacerb
known
interest
obes
associ
product
proinflammatori
factor
chemokin
anim
model
human
factor
includ
eotaxin
eosinophil
chemoattract
increas
sputum
acut
asthma
well
leptin
tnfa
howev
seem
relationship
bmi
sputum
eosinophil
count
suggest
altern
inflammatori
mechan
may
contribut
obes
asthmat
asthmat
may
rare
intermitt
exacerb
evid
subset
asthmat
exacerbationpron
exampl
among
patient
present
us
emerg
depart
acut
asthma
report
least
one
visit
asthma
prior
year
report
six
visit
factor
nonwhit
race
medicaid
insur
public
insur
marker
asthma
sever
predict
risk
frequent
visit
data
suggest
patient
present
recurr
exacerb
prone
risk
relat
social
factor
poor
access
care
inadequ
chronic
asthma
control
also
possibl
exacerb
present
emerg
depart
may
caus
asthma
vocal
cord
dysfunct
howev
data
epidemiolog
studi
difficulttocontrol
asthmat
popul
provid
evid
intrins
phenotyp
exacerbationpron
asthma
epidemiolog
natur
histori
asthma
outcom
treatment
regimen
studi
multicentr
observ
studi
natur
histori
treatment
regimen
outcom
sever
difficulttotreat
asthmat
unit
state
prospect
analysi
adult
patient
histori
recent
sever
exacerb
requir
emerg
room
visit
hospit
past
month
significantli
increas
risk
recurr
futur
exacerb
odd
ratio
confid
interv
risk
independ
demograph
clinic
factor
asthma
sever
asthma
control
thu
like
subgroup
asthmat
whose
suscept
exacerb
independ
tradit
measur
asthma
control
sever
import
epidemiolog
studi
provid
evid
exacerbationpron
asthma
nation
heart
lung
blood
institut
sever
asthma
research
program
identifi
asthmat
mild
moder
sever
diseas
base
criteria
includ
inhal
oral
corticosteroid
use
control
medic
use
airflow
obstruct
histori
nearfat
event
notabl
signific
percentag
asthmat
multipl
exacerb
requir
three
burst
oral
corticosteroid
per
year
rang
across
level
sever
mild
moder
sever
near
fatal
event
also
infrequ
among
group
mild
moder
sever
addit
casecontrol
studi
demonstr
asthmat
multipl
exacerb
compar
singl
exacerb
increas
risk
sever
exacerb
defin
initi
escal
system
corticosteroid
despit
intens
mainten
antiinflammatori
treatment
characterist
featur
exacerbationpron
subject
includ
irrevers
airflow
limit
chronic
sinus
psycholog
dysfunct
intoler
nonsteroid
antiinflammatori
medic
exacerbationpron
asthmat
belong
distinct
group
experi
nearfat
episod
asthma
character
acut
respiratori
failur
requir
mechan
ventil
treatment
intens
care
unit
european
network
understand
mechan
sever
asthma
character
subject
sever
asthma
found
subgroup
prior
nearfat
asthma
nfa
differ
asthmat
sever
group
respect
reduc
complianc
prescrib
asthma
medic
less
corticosteroid
use
interestingli
nfa
group
similar
mildtomoder
rather
sever
asthmat
regard
clinic
inflammatori
paramet
studi
confirm
asthmat
suffer
near
fatal
exacerb
distinguish
lung
function
ahr
durat
asthma
gender
smoke
statu
ethnic
preval
atopi
distinguish
medic
noncompli
poor
asthma
control
less
corticosteroid
use
asthmat
experi
near
fatal
exacerb
import
subgroup
asthma
better
intervent
educ
complianc
use
inhal
corticosteroid
might
reduc
incid
recurr
near
fatal
event
addit
associ
admiss
intens
care
unit
skin
test
sensit
fungal
allergen
includ
alternaria
cladosporium
result
crosssect
studi
need
replic
studi
possibl
environment
intervent
reduc
exposur
mould
could
help
reduc
frequenc
asthma
exacerb
certain
asthmat
asthma
associ
acceler
loss
lung
function
although
like
subgroup
asthmat
drive
associ
minor
asthmat
one
cohort
studi
difficulttocontrol
asthmat
develop
degre
irrevers
airflow
obstruct
subgroup
asthmat
patient
chronic
airflow
obstruct
increas
risk
acut
asthma
exacerb
reduc
forc
expiratori
volum
fev
shown
import
risk
factor
multipl
asthma
exacerb
requir
either
hospit
care
system
corticosteroid
relationship
fev
risk
asthma
exacerb
could
exacerb
caus
promot
longterm
reduct
lung
function
altern
relationship
may
result
specif
type
airway
inflamm
specif
host
factor
smoke
increas
risk
exacerb
lung
function
declin
recent
retrospect
cohort
studi
provid
evid
favour
exacerb
independ
risk
acceler
loss
lung
function
specif
effect
sever
exacerb
defin
hospit
decreas
fev
ml
progress
airway
obstruct
evalu
nonsmok
asthmat
moderatetosever
diseas
treatment
inhal
corticosteroid
asthmat
experienc
least
one
sever
exacerb
acceler
loss
lung
function
compar
exacerb
relationship
exacerb
acceler
loss
lung
function
independ
airflow
obstruct
baselin
inde
one
sever
exacerb
per
year
associ
ml
greater
annual
declin
fev
sever
airflow
obstruct
year
followup
possibl
explan
multipl
inflammatori
pathway
activ
acut
exacerb
includ
elev
matrix
metalloproteinas
may
longterm
consequ
airway
remodel
result
airway
narrow
way
asthma
exacerb
may
becom
selfperpetu
one
exacerb
caus
chang
lung
function
promot
subsequ
exacerb
cycl
may
help
explain
exacerbationpron
phenotyp
fig
airflow
obstruct
asthma
exacerb
occur
concentr
smooth
muscl
contract
airway
wall
oedema
lumin
obstruct
mucu
role
mucu
plug
emphas
patholog
studi
fatal
case
asthma
show
airway
invari
impact
mucu
nfa
also
frequent
associ
segment
subsegment
lung
collaps
mucu
plug
fig
precipit
acut
asthma
exacerb
numer
includ
virus
allergen
dust
mite
pollen
anim
dander
occup
exposur
grain
flour
clean
agent
metal
irrit
wood
hormon
menstrual
asthma
drug
asa
nonsteroid
antiinflammatori
drug
nsaid
bblocker
exercis
stress
air
pollut
asthma
heterogen
diseas
like
differ
extrins
precipit
exacerb
less
import
differ
individu
environment
caus
asthma
exacerb
heterogen
common
upper
respiratori
tract
virus
especi
rhinovirus
common
import
caus
chest
radiograph
woman
admit
intens
care
unit
manag
acut
sever
asthma
chest
radiograph
show
collaps
right
upper
lobe
secondari
mucu
impact
abnorm
resolv
complet
within
h
treatment
mechan
ventil
corticosteroid
bronchodil
reproduc
permiss
fahi
exacerb
children
adult
develop
pcr
techniqu
viral
detect
multipl
communitybas
studi
consist
shown
exampl
studi
children
experienc
asthma
exacerb
decreas
peak
flow
rate
virus
detect
airway
secret
case
rhinovirus
commonli
detect
viru
studi
report
rate
viral
infect
acut
asthma
rhinovirus
coronavirus
common
culprit
viral
caus
includ
influenza
parainfluenza
respiratori
syncyti
viru
chlamydia
pneumonia
mycoplasma
pneumonia
newer
viru
detect
method
dna
microarraybas
viral
detect
method
show
multipl
serotyp
rhinovirus
detect
airway
secret
respiratori
infect
asthmat
respiratori
viral
infect
commonli
associ
asthma
exacerb
probabl
multipl
addit
factor
contribut
airway
inflamm
result
acut
asthma
exampl
appear
synergist
interact
exposur
high
level
allergen
viral
infect
caus
sever
deterior
asthma
exampl
casecontrol
studi
adult
patient
compar
hospit
acut
asthma
two
control
group
patient
stabl
asthma
patient
hospit
nonasthma
condit
compar
control
significantli
higher
proport
acut
asthmat
sensit
expos
allergen
includ
dust
mite
cat
dog
allergen
vs
respect
interestingli
combin
sensit
high
exposur
one
allergen
viral
detect
significantli
increas
risk
hospit
asthma
compar
control
stabl
asthma
evid
interact
virus
allergen
come
allergen
challeng
experi
subject
challeng
allergen
intranas
inocul
rhinoviru
increas
latephas
allergen
respons
histamin
ragwe
cold
find
corrobor
studi
use
segment
airway
challeng
infect
rhinoviru
allerg
rhiniti
subject
infect
rhinoviru
challeng
allergen
cold
greater
histamin
releas
h
allergen
challeng
well
greater
recruit
eosinophil
airway
h
afterward
effect
persist
month
follow
infect
observ
nonatop
subject
viral
infect
like
caus
inflamm
prime
airway
enhanc
respons
allergen
exposur
like
viral
allerg
mechan
act
cooper
creat
acut
sever
asthmat
respons
understand
role
virus
acut
asthma
studi
biolog
rhinoviru
infect
predomin
viru
caus
exacerb
rhinoviru
affect
upper
lower
airway
primarili
infect
epitheli
cell
line
airway
close
contact
environ
infect
airway
epitheli
cell
produc
varieti
proinflammatori
mediat
includ
ifninduc
protein
kda
regul
activ
normal
cell
express
rant
granulocyt
macrophagecoloni
stimul
factor
eotaxin
fig
cytokin
chemokin
recruit
inflammatori
cell
neutrophil
lymphocyt
eosinophil
airway
neutrophil
predomin
inflammatori
cell
detect
airway
secret
acut
exacerb
subject
report
respiratori
tract
infect
trigger
exacerb
significantli
higher
percentag
neutrophil
sputum
probabl
caus
increas
epitheli
product
potent
chemoattract
neutrophil
although
corticosteroid
reduc
epitheli
cell
express
sever
chemokin
rant
may
effect
inhibit
virusinduc
pathway
inflamm
effect
prevent
virusinduc
exacerb
remain
controversi
besid
elabor
inflammatori
chemokin
recruit
inflammatori
cell
infect
epitheli
cell
rhinoviru
also
activ
sever
import
antivir
pathway
part
innat
immun
respons
rhinoviru
bind
receptor
intercellular
adhes
molecul
icam
surfac
epitheli
cell
viru
intern
undergo
replic
doublestrand
rna
byproduct
viral
replic
bind
tolllik
receptor
activ
intracellular
signal
nuclear
factork
b
pathway
result
elabor
type
interferon
ifna
ifnb
ifn
activ
programm
antivir
gene
act
limit
viral
replic
viral
spread
neighbour
epitheli
cell
adapt
immun
respons
may
also
import
limit
viral
replic
rhinoviru
infect
stimul
product
thelper
type
cytokin
includ
ifng
peripher
blood
mononuclear
cell
ifng
similar
antivir
activ
ifna
ifnb
includ
upregul
class
mhc
inhibit
viral
replic
induct
sever
ifnsensit
gene
clinic
studi
show
decreas
gener
ifng
associ
sever
cold
increas
sever
acut
asthma
cytokin
induc
rhinoviru
infect
acut
asthma
differ
product
cytokin
typic
chronic
asthma
balanc
cytokin
may
import
determin
sever
exacerb
exampl
experiment
infect
asthmat
subject
rhinoviru
ratio
sputum
ifng
correl
invers
peak
cold
symptom
time
viru
clearanc
suggest
gener
robust
respons
may
import
limit
effect
viral
airway
infect
failur
gener
respons
may
increas
risk
virusassoci
asthma
exacerb
fig
clear
subset
asthmat
particularli
suscept
recurr
exacerb
risk
exacerb
function
complex
interplay
pathogen
specif
respiratori
virus
rhinovirus
host
airway
suscept
factor
environment
modifi
exposur
cigarett
smoke
suscept
factor
divid
caus
extrins
intrins
asthmat
airway
fig
exampl
extrins
risk
factor
cigarett
smoke
among
patient
hospit
acut
asthma
infect
rhinoviru
like
current
smoker
high
preval
current
smoke
adult
present
acut
asthma
emerg
depart
addit
smoke
found
power
independ
modifi
risk
factor
multipl
exacerb
requir
hospit
care
prospect
hmobas
studi
anoth
import
modifi
risk
factor
studi
exposur
allerg
sensit
cat
dog
underscor
interact
allerg
viral
caus
cigarett
smoke
sever
effect
airway
could
promot
asthma
exacerb
exampl
cigarett
smoke
associ
airway
neutrophilia
chang
airway
epitheli
mucin
store
could
affect
viral
clearanc
airway
fig
import
extrins
suscept
factor
includ
comorbid
chronic
rhinosinus
histori
pneumonia
obes
gerd
intoler
nsaid
psychosoci
factor
depress
poor
social
support
public
insur
unemploy
play
import
role
well
recent
excit
advanc
made
understand
suscept
factor
intrins
asthmat
airway
could
promot
exacerb
subset
asthmat
specif
experiment
model
infect
primari
bronchial
epitheli
cell
asthmat
healthi
subject
rhinoviru
shown
epitheli
cell
healthi
subject
quit
resist
infect
cell
asthmat
enhanc
viral
replic
cell
lysi
addit
apoptosi
rather
direct
lysi
infect
cell
import
control
viral
product
releas
inflammatori
mediat
earli
induct
apoptosi
dramat
impair
asthmat
vs
healthi
cell
furthermor
asthmat
cell
defici
product
ifnb
earli
import
antivir
cytokin
exogen
ifnb
restor
apoptosi
defect
asthmat
cell
inhibit
viral
replic
suggest
antivir
pathway
intact
asthmat
cell
defici
activ
key
antivir
cytokin
fig
similar
result
also
discov
ifnl
novel
type
iii
ifn
similar
antivir
properti
defici
observ
whether
asthmat
take
inhal
corticosteroid
defect
asthmat
epitheli
cell
also
extend
macrophag
asthmat
also
defici
ifn
product
data
import
defici
antivir
respons
rhinoviru
infect
could
enhanc
viral
replic
cell
damag
product
proinflammatori
cytokin
result
exacerb
asthma
time
mechan
suboptim
antivir
respons
poorli
understood
specif
intervent
remedi
avail
evid
intrins
host
defect
come
genet
studi
import
cytokin
promot
product
ige
b
cell
two
polymorph
receptor
gene
associ
increas
risk
sever
exacerb
lower
lung
function
two
independ
cohort
polymorph
common
african
american
confer
similar
risk
african
american
caucasian
one
polymorph
also
associ
increas
tissu
mast
cell
higher
level
ige
bound
mast
cell
pharmacolog
intervent
shown
success
reduc
asthma
exacerb
includ
inhal
corticosteroid
longact
bagonist
leukotrien
modifi
antiig
therapi
recent
systemat
review
metaanalysi
compar
strategi
demonstr
inhal
corticosteroid
success
reduc
exacerb
compar
placebo
shortact
bagonist
alon
longact
bagonist
reduc
exacerb
compar
placebo
also
reduc
exacerb
ad
inhal
corticosteroid
leukotrien
modifi
import
antiinflammatori
effect
may
reduc
exacerb
much
compar
placebo
howev
inferior
inhal
corticosteroid
reduc
exacerb
less
effect
longact
bagonist
addon
therapi
alreadi
take
inhal
corticosteroid
inhal
corticosteroid
quit
effect
reduc
exacerb
poor
complianc
inhal
corticosteroid
risk
factor
recurr
exacerb
well
nfa
corticosteroid
shown
enhanc
innat
immun
epitheli
host
defens
reduc
proinflammatori
cytokin
product
may
explain
role
reduc
asthma
exacerb
furthermor
rhinoviru
infect
epitheli
cell
lead
upregul
viral
receptor
wherea
corticosteroid
inhibit
induct
rhinoviru
corticosteroid
also
reduc
ahr
strategi
might
lead
better
control
exacerb
despit
clear
benefit
asthmat
risk
exacerb
gener
undertr
inhal
corticosteroid
emphasi
asthma
exacerb
specif
outcom
asthma
therapi
recent
guidelin
nihnhlbi
nation
asthma
educ
prevent
program
help
educ
provid
need
corticosteroid
use
patient
fewer
daili
symptom
recurr
exacerb
recogn
exacerb
occur
even
asthmat
use
chronic
system
corticosteroid
highlight
need
continu
work
toward
effect
mechanismtarget
therapi
omalizumab
human
monoclon
antibodi
ige
shown
promis
prevent
asthma
exacerb
treatment
omalizumab
significantli
reduc
level
circul
ige
well
tissu
sputum
eosinophil
interestingli
omalizumab
reduc
exacerb
approxim
even
patient
take
high
dose
inhal
corticosteroid
despit
modest
effect
lung
function
ahr
effect
therapi
underscor
import
develop
therapi
specif
aim
reduc
exacerb
primari
outcom
clinic
trial
howev
protein
therapeut
omalizumab
expens
cost
effect
omalizumab
hotli
debat
level
sputum
eosinophil
predict
increas
risk
exacerb
strategi
target
sputum
eosinophil
antiinflammatori
therapi
reduc
rate
exacerb
context
measur
exhal
nitric
oxid
optim
antiinflammatori
therapi
relev
level
exhal
nitric
oxid
feno
correl
number
sputum
eosinophil
measur
less
invas
clinic
studi
shown
feno
use
biomark
guid
reduct
corticosteroid
dose
without
increas
rate
exacerb
whether
feno
measur
ultim
prove
benefici
reduc
asthma
exacerb
remain
seen
asthma
highli
preval
global
health
problem
signific
morbid
mortal
cost
larg
driven
acut
care
visit
diseas
includ
clinic
emerg
room
visit
hospit
minor
asthmat
approxim
respons
major
health
care
cost
associ
exacerb
subset
asthmat
exacerbationpron
clinic
characterist
subgroup
includ
histori
cigarett
smoke
psychosoci
factor
medic
noncompli
comorbid
rhinosinus
obes
gerd
nsaid
intoler
intrins
host
factor
asthma
subgroup
begin
identifi
defici
epitheli
cell
product
antivir
type
ifn
mechanist
studi
human
focus
exacerbationpron
asthmat
import
better
understand
develop
new
prevent
treatment
aim
reduc
signific
cost
morbid
associ
asthma
